Publications by authors named "E Pastor-Villalba"
Article Synopsis
- The study aims to assess the effectiveness of hepatitis B preventive measures to prevent vertical transmission from mothers to newborns in Spain, in line with WHO strategies.
- The research involved a retrospective analysis of data from women who gave birth in 2022 across four regions in Spain, utilizing various clinical databases to evaluate screening and vaccination practices.
- Findings indicated high screening coverage (76% to 99.3%) but varying compliance rates (30.6% to 100%) across regions, highlighting the need for improved awareness and data management among healthcare professionals to enhance preventive efforts.
Article Synopsis
- This study evaluates nirsevimab, a monoclonal antibody, for preventing respiratory syncytial virus (RSV) infections in infants under ten months in Spain.
- It involved a large immunization campaign where infants born after April 1, 2023, received nirsevimab either at birth or through a catch-up program.
- Results showed nirsevimab had an overall effectiveness of 75.8% and 80.2% in the catch-up group, highlighting its role in reducing RSV-related illnesses in primary care settings.
Public funding of vaccines may enhance vaccination rates, co-administration, and timeliness. The impacts of including the serogroup B meningococcus vaccine (MenB) into the national immunisation schedule on vaccination rates, co-administration rates, and timeliness were assessed using a population-based pre-funding (2022) and post-funding (2023) study design. MenB vaccination rates improved after funding and were in line with previously funded vaccines.
View Article and Find Full Text PDFArticle Synopsis
- Respiratory syncytial virus (RSV) is a major cause of illness and hospitalization in young children, particularly those under 1 year old.
- In the Valencian Community of Spain, a new monoclonal antibody called nirsevimab was introduced for high-risk children and those under 6 months as a preventive measure for the 2023-2024 RSV season.
- Preliminary results indicate that the immunization campaign achieved 88.5% coverage, with immunized children showing a threefold reduction in RSV incidence and lower hospitalization rates for respiratory infections compared to those who were not immunized.
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
Mónica López-Lacort Cintia Muñoz-Quiles Ainara Mira-Iglesias F Xavier López-Labrador Beatriz Mengual-Chuliá Eliseo Pastor-Villalba
Euro Surveill
February 2024
Article Synopsis
- * This effectiveness was validated through two different research methods (screening and test-negative) in a multicenter study across nine hospitals in three regions.
- * The antibody did not provide any protection against hospitalizations for lower respiratory tract infections caused by viruses other than RSV, and these findings could help influence public health policies.